Zasocitinib: A Breakthrough Oral Treatment for Plaque Psoriasis - Phase 3 Study Results
Takeda has unveiled new data from Phase 3 studies of zasocitinib, a highly selective oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. The data, presented at the 2026 American Academy of Dermatology Annual Meeting, demonstrate that zasocitinib offers rapid and lasting skin clearance with a favorable safety profile. The studies showed that over half of patients treated with zasocitinib achieved clear or almost clear skin at week 16, a significant treatment milestone. Zasocitinib also showed improvements in complete skin clearance, highlighting its potential as an oral treatment option for plaque psoriasis. The Phase 3 studies revealed rapid response as early as week 4, with a high percentage of patients maintaining their response at week 60. Zasocitinib was well-tolerated, with a safety profile consistent with prior studies. Takeda is working towards regulatory submissions to make zasocitinib available as a new therapeutic option for patients seeking an effective and convenient oral treatment for psoriasis.
Psoriasis is a chronic inflammatory disease characterized by rapid skin cell multiplication, resulting in itchy, painful, and scaly patches on the skin. Plaque psoriasis, the most common form, can affect various parts of the body and significantly impact patients' quality of life. Zasocitinib, an investigational TYK2 inhibitor, has shown promising results in maintaining 24-hour inhibition of key immune pathways involved in psoriasis. With its high selectivity for TYK2, zasocitinib could offer a targeted approach to treating immune-mediated inflammatory diseases. Takeda is evaluating zasocitinib in head-to-head studies and Phase 3 trials for various conditions, including psoriatic arthritis and inflammatory bowel diseases. The Phase 3 studies have not affected Takeda's financial forecast for the current fiscal year.
Takeda will host an investor call to discuss the Phase 3 data and market potential for zasocitinib, emphasizing its commitment to advancing innovative treatments for patients. Psoriasis affects millions of people globally, with plaque psoriasis being the most common form. Zasocitinib's unique mechanism of action as a TYK2 inhibitor offers a promising therapeutic approach for immune-mediated inflammatory diseases. The Phase 3 studies have demonstrated zasocitinib's efficacy and safety in achieving clear or nearly clear skin, highlighting its potential as a leading oral treatment option for plaque psoriasis. Takeda's focus on creating better health for patients aligns with its mission to deliver life-transforming treatments and improve patient outcomes.